Use of heterocyclic compounds for the treatment of conditions caused by malfunctioning of the nicotinic cholinergic system
AssigneeNovo Nordisk A/S
InventorPreben Houlberg Olesen
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of azabicyclic compounds for the treatment of diseases caused by malfunctioning of the nicotinic cholinergic system. These diseases treated include obesity, Parkinson's disease, anxiety, and ulcerative colitis.
Claims10
A method of treating a disease caused by malfunctioning of the nicotinic cholinergic system other than Alzheimer's disease, Tourrette's syndrome, and severe pain in a subject in need thereof comprising administering to said subject an effective amount of a compound of formula I ##STR6## wherein p is 1 and either m is 0 and n is 1 or 2 or m is 1 and n is 1, or p is 2, m is 0 and n is 1;
- and
- wherein Y is ##STR7## wherein -A-B-C-D- is selected from .dbd.C(R.sup.1)--O--N.dbd.C(R.sup.2)--, .dbd.C(R.sup.1)--S--N.dbd.C(R.sup. 2)--, .dbd.C(R.sup.1)--N.dbd.C(R.sup.2)--O--, .dbd.C(R.sup.1)--C(R.sup.2).dbd.C(R.sup.3)--O--, .dbd.C(R.sup.1)--C(R.sup.2).dbd.N--O--, .dbd.C(R.sup.1)--N.dbd.C(R.sup.2)--S--, .dbd.C(R.sup.1)--C(R.sup.2).dbd.C(R.sup.3)--S--, .dbd.C(R.sup.1)--C(R.sup.2).dbd.N--S--, --C(R.sup.1).dbd.C(R.sup.2)--O--C(R.sup.3).dbd., --C(R.sup.1).dbd.C(R.sup.2)--S--C(R.sup.3).dbd., --N(R.sup.4)--N.dbd.C(R.sup.1)--C(R.sup.2).dbd., .dbd.N--N(R.sup.4)--C(R.sup.1).dbd.C(R.sup.2)--, .dbd.N--O--C(R.sup.1).dbd.C(R.sup.2)--, .dbd.N--S--C(R.sup.1).dbd.C(R.sup.2)--, --N(R.sup.4)--C(R.sup.1).dbd.N--C(R.sup.2).dbd., --N.dbd.C(R.sup.1)--N(R.sup.4)--C(R.sup.2).dbd., .dbd.C(R.sup.1)--N(R.sup.4)--N.dbd.C(R.sup.2)--, --N.dbd.C(R.sup.1)--O--C(R.sup.2).dbd., --N.dbd.C(R.sup.1)--S--C(R.sup.2).dbd., .dbd.N--C(R.sup.1).dbd.C(R.sup.2)--N(R.sup.4)--, .dbd.N--C(R.sup.1).dbd.C(R.sup.2)--O--, .dbd.N--C(R.sup.1).dbd.C(R.sup.2)--S--, --N(R.sup.4)--N.dbd.N--C(R.sup.1).dbd., .dbd.N--N(R.sup.4)--N.dbd.C(R.sup.1)--, --N.dbd.N--N(R.sup.4)--C(R.sup.1).dbd., --N(R.sup.4)--N.dbd.C(R.sup.1)--N.dbd., .dbd.N--N(R.sup.4)--C(R.sup.1).dbd.N--, .dbd.N--N.dbd.C(R.sup.1)--N(R.sup.4)--, .dbd.N--O--N.dbd.C(R.sup.1)--, .dbd.N--N.dbd.C(R.sup.1)--O--, --N.dbd.C(R.sup.1)--O--N.dbd., .dbd.N--C(R.sup.1).dbd.N--O--, .dbd.N--N.dbd.C(R.sup.1)--S--, .dbd.N--S--N.dbd.C(R.sup.1)--, .dbd.N--C(R.sup.1).dbd.N--S--, --N.dbd.C(R.sup.1)--S--N.dbd., --N(R.sup.4)--N.dbd.N--N.dbd. and .dbd.N--N(R.sup.4)--N.dbd.N--;
- and
- R.sup.1, R.sup.2 and R.sup.3 independently are hydrogen, halogen, NR.sup.5 R.sup.6, C.sub.2-3 -alkenyl, C.sub.2-3 -alkynyl or C.sub.1-2 -alkyl optionally substituted with one, two or three fluorine atoms;
- and
- R.sup.4 is C.sub.1-2 -alkyl, cyclopropyl or propargyl;
- and
- R.sup.5 and R.sup.6 independently are hydrogen or methyl, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.